Microcap Ledger Cadrenal Therapeutics, Inc. $CVKD
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Ponte Vedra, FL
- Fiscal year end
- December 31
- Shares outstanding
- 3,567,592 [10-Q 2026-08-13]
What the company doesAI summary of filing
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing therapies for immune-mediated and thrombotic disorders. The company's lead product candidate, CAD-1005, is a first-in-class selective 12-lipoxygenase inhibitor in clinical development for heparin-induced thrombocytopenia (HIT). The company also develops tecarfarin, an oral vitamin K antagonist in late-stage development for patients with kidney dysfunction or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor in Phase 2-ready development for acute care settings. Cadrenal is pre-revenue and has no approved products on the market. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$5.82M | −$5.24M | $2.39M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$13.24M | −$12.60M | $4.01M | [10-K 2026-03-31] |
| FY ended Dec 2024 | — | −$10.65M | −$7.36M | $10.02M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$2.62M
- Cash runway Estimate
- ~2.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 1,658,771 | [10-Q 2024-11-07] |
| 2025-03-13 | 1,879,710 | [10-K 2025-03-13] |
| 2025-05-08 | 1,966,675 | [10-Q 2025-05-08] |
| 2025-08-11 | 2,046,854 | [10-Q 2025-08-11] |
| 2025-11-10 | 2,075,845 | [10-Q 2025-11-10] |
| 2026-03-27 | 2,506,817 | [10-K 2026-03-31] |
| 2026-05-06 | 2,868,247 | [10-Q 2026-05-07] |
| 2026-08-13 | 3,567,592 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-07-13; declared effective 2026-07-20 [S-3 2026-07-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-29 | Pham Quang X | sell | 7,400 | $3.03 | [4 2026-07-01] |
| 2026-06-26 | Pham Quang X | sell | 9,029 | $3.05 | [4 2026-06-26] |
| 2026-06-25 | Pham Quang X | sell | 2,127 | $3.00 | [4 2026-06-26] |
| 2026-06-23 | Pham Quang X | sell | 2,277 | $3.20 | [4 2026-06-24] |
| 2026-06-22 | Pham Quang X | sell | 9,167 | $3.55 | [4 2026-06-24] |
| 2026-06-17 | Pham Quang X | sell | 513 | $3.16 | [4 2026-06-18] |
| 2026-06-16 | Pham Quang X | sell | 3,613 | $3.18 | [4 2026-06-18] |
| 2026-06-15 | Pham Quang X | sell | 3,666 | $3.58 | [4 2026-06-15] |
| 2026-06-12 | Pham Quang X | sell | 12,996 | $3.94 | [4 2026-06-15] |
| 2026-06-11 | Pham Quang X | sell | 1,462 | $4.12 | [4 2026-06-15] |
| 2026-06-10 | Pham Quang X | sell | 3,500 | $4.21 | [4 2026-06-10] |
| 2026-06-09 | Pham Quang X | sell | 12,992 | $4.06 | [4 2026-06-10] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-29 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-31 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | DEF 14A | Proxy statement |
| 2026-07-23 | PRE 14A | Proxy statement |
| 2026-07-21 | 8-K | Regulation FD disclosure; Other events |
| 2026-07-20 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-17 | 8-K | Director or officer change |
| 2026-07-13 | S-3 | Registration statement |
Alerts for $CVKD
Email me when Cadrenal Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.